RPG LifeScience. Q2 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Revenue guidance
See what RPG LifeScience. management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what RPG LifeScience. management said on order book — free account, 30 seconds.
Capex plans
Track RPG LifeScience. — get its next earnings analysis in your feed
How does RPG LifeScience. rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does RPG LifeScience. rank in Pharmaceuticals & Biotechnology?
Compare RPG LifeScience. against every Pharmaceuticals & Biotechnology company (Q2 FY22) on revenue, margins and earnings-call signals.
Continue your research
What RPG LifeScience.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Beta Drugs Ltd (Q2 FY27)
H1 FY25: ₹180 Crs . Key investor presentation takeaways from Beta Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
- Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
- Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…